Mirum Pharmaceuticals, Inc. Capital Expenditures Incurred but Not yet Paid
Mirum Pharmaceuticals, Inc. (MIRM) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2021-08-05
- Mirum Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2020-09-30 was -$42.00K, a 197.67% decline year-over-year.
- Mirum Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2019-09-30 was $43.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month |
|---|---|---|---|
| 2020-09-30 | -$42.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $42.00K 10-Q · filed 2021-08-05 | ||
| 2019-09-30 | $43.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $43.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |